6 completed, 1 terminated, 1 withdrawn. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Stage IV Fallopian Tube Cancer: new trials by email Literature Review of Stage IV Fallopian Tube Cancer trials Research Report on Stage IV Fallopian Tube Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Quality-of-Life Assessment, Questionnaire Administration - Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 50 | 2019-01-02 | 2026-08-21 |
| IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer | Phase 2 | Terminated | University of Washington | 11 | 2017-04-03 | 2022-01-14 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine, IDO1 inhibitor INCB024360, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-12-01 | 2013-12-18 | |
| OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821 - Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer | Phase 2 | Completed | Gynecologic Oncology Group | 171 | 2010-07-01 | 2017-09-13 |
| RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2010-07-01 | 2017-05-24 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer sunitinib malate, laboratory biomarker analysis - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2007-01-01 | 2015-01-27 |
Fallopian Tube Neoplasms (8) · Ovarian Neoplasms (5) · Carcinoma, Ovarian Epithelial (3) · Brenner Tumor (1) · Carcinoma, Hepatocellular (1) · Pleural Effusion, Malignant (1) · Somatostatinoma (1)
Adnexal Diseases (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Fallopian Tube Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genital Diseases (8) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Gonadal Disorders (8) · Neoplasms (8) · Neoplasms by Site (8) · Ovarian Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8)
Carboplatin (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Bevacizumab (1) · Cytoreduction Surgical Procedures (1) · Disulfides (1) · Drug Therapy (1) · Gynecologic Surgical Procedures (1) · Immunoglobulin G (1) · Metformin (1) · Paclitaxel (1) · Sirolimus (1) · Sunitinib (1) · Surgical Procedures, Operative (1) · Taxes (1) · epacadostat (1)
National Cancer Institute (NCI) (3) · Gynecologic Oncology Group (1) · Roswell Park Cancer Institute (1) · University of Chicago (1) · University of Washington (1) · Wake Forest University Health Sciences (1)
United States (6) · Canada (3)
Amit Oza (1) · Henry Pitot (1) · James Biagi (1) · John Liao (1) · Kunle Odunsi (1) · Michael Kelly (1) · Paul Sabbatini (1) · Seiko Yamada (1)
PMID 25318437, PMID 25488966, PMID 31653510, PMID 37702588
N01CM00032 (2), N01CM00038 (2), N01CM00071 (2), N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), N01CM00039 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), N01CM62208 (1)